I suspect that enrollment will indeed take about that 'year' - unless some big pharma with deep pockets signs on an starts opening some doors for them and shaking the 'money tree' to grease the skids. That could speed things up by at least a couple of months.
And yes - the tumor shrinkage and disease regression data will be available, if not collated and easily analyzable within weeks for each patient. Anecdotal data will be available, but getting the data organized enough to critically analyze is going to take time. If whatever CRO or deep pockets supporter is on the ball and organized, that is still likely to take months post the trial being filled. Again - it's going to take somebody organized and that will have money to throw at the problem to speed things up more than that.
I do think that a conditional approval for Multikine, based on beneficial tumor regression data, is possible by sometime in 2026 as well.
It's going to be an interesting ride here in the meantime.
Have a good weekend folks.
News 
Market Data 
Discover 
